2. Search Result
Search Result
Results for "

relapsed cancer

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Inhibitory Antibodies

Targets Recommended:
Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-101563
    GSK3326595
    Maximum Cited Publications
    31 Publications Verification

    EPZ015938

    		 Histone Methyltransferase SARS-CoV MDM-2/p53 CDK Apoptosis Infection Cancer
    GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .
    GSK3326595
  • HY-112037
    IACS-010759
    25+ Cited Publications

    IACS-10759

    		 Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis Cancer
    IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research .
    IACS-010759
  • HY-125399
    PSMA-11
    1 Publications Verification

    HBED-CC-PSMA

    		 PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
    PSMA-11
  • HY-114778
    Fluzoparib
    4 Publications Verification

    SHR3162; Fuzuloparib

    		 PARP Cancer
    Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC50=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .
    Fluzoparib
  • HY-P991537
    Risvutatug

    HS-20093 Antibody; GSK5764227 Antibody

    		 ADC Antibody CD276/B7-H3 Cancer
    HS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors .
    Risvutatug
  • HY-45661
    Inixaciclib

    NUV-422

    		 CDK Neurological Disease Cancer
    Inixaciclib (NUV-422) is a blood-brain barrier-penetrant inhibitor of CDK2, CDK4 and CDK6. Inixaciclib inhibits cancer cell growth. Inixaciclib induces anti-tumor activity in xenograft models of glioblastoma, CDK4/CDK6 inhibitor-resistant HR + HER2 - metastatic breast cancer, and anti-androgen-resistant prostate cancer. Inixaciclib can be used for the research of relapsed or metastatic castration-resistant prostate cancer .
    Inixaciclib
  • HY-112037A
    IACS-010759 hydrochloride
    25+ Cited Publications

    IACS-10759 hydrochloride

    		 Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis Cancer
    IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research .
    IACS-010759 hydrochloride
  • HY-160215
    GFH018

    		TGF-β Receptor p38 MAPK TGF-beta/Smad Interleukin Related Cancer
    GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
    GFH018
  • HY-150403
    XF067-68

    		PROTACs WDR5 Cancer
    XF067-68 (example 132) is a PROTAC for targeted degradation of WD40 repeat domain protein 5 (WDR5). XF067-68 can be usde for the study of WDR5-mediated diseases. (Pink: target protein ligand (HY-141799); Blue: E3 ligase ligand (HY-173627); Black: linker (HY-Y0966); E3 ligase ligand + linker: HY-176517) .
    XF067-68
  • HY-160215A
    GFH018 methylbenzenesulfonate

    		TGF-β Receptor p38 MAPK TGF-beta/Smad Interleukin Related Cancer
    GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
    GFH018 methylbenzenesulfonate
  • HY-P991173
    AMG-119

    		Notch Cancer
    AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    AMG-119
  • HY-101563R
    GSK3326595 (Standard)

    EPZ015938 (Standard)

    		 Histone Methyltransferase Reference Standards SARS-CoV MDM-2/p53 CDK Apoptosis Infection Cancer
    GSK3326595 (Standard) is the analytical standard of GSK3326595 (HY-101563). This product is intended for research and analytical applications. GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .
    GSK3326595 (Standard)
  • HY-183596
    L-His-BPA

    		Drug Intermediate Cancer
    L-His-BPA is a prodrug of L-p-Boronophenylalanine (L-BPA) (HY-W087830), formed by the peptide bond linkage of L-histidine (L-His) (HY-N0832) and L-BPA. L-His-BPA is rapidly cleaved by endogenous proteases to de novo release L-BPA in the systemic circulation. When used in combination with neutron irradiation, L-His-BPA induces complete and durable tumor regression, elicits cancer vaccine responses, and produces abscopal inhibitory effects on unirradiated distant tumors. L-His-BPA can be used in studies of boron neutron capture therapy (BNCT) for relapsed/advanced solid tumors .
    L-His-BPA

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: